Back to results
US 8,075,908 B2Granted
Apparatus and method for reducing the occurrence of post-surgical adhesions
AssigneeAnhese LLC
InventorJohn P. Delaney
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeAnhese LLC
InventorJohn P. Delaney
Estimating the term…
A method for inhibiting formation of adhesions following abdominal surgery which involves application of an anti-static fatty acid ethoxylated amide (Cocamide DEA) in a matrix that is placed in the peritoneal cavity at the conclusion of an abdominal surgery and which releases this anti-adhesive chemical over a predetermined time in a range from about five to seven days. Tests conducted on laboratory rats established that the method reduced the incidences of adhesions from 100 percent (100%) in a test model to near zero percent (0%) in the treated animals. In an alternative embodiment, Andrographalide was delivered through a drug pump with similar results. In still another embodiment, an effective amount of Rapamune was delivered, via a pump, into the abdominal cavity, again with similar results.
A method of inhibiting formation of adhesions, post surgery, which comprises delivering an effective amount of a mixture of rapamycin in solution of at least 50% phosphatidylcholine, lecithin in propylene glycol, sunflower mono-diglycerides, ascorbyl palmitate, propylene glycol, polysorbate 80, and 1.5%-2.5% ethanol into the abdominal cavity over a predetermined time interval.
A composition suitable for local, non-systemic administration of a drug topically to tissue within a body cavity having been subjected to a surgical procedure, said composition comprising a mixture of rapamycin in a solution of at least 50% phosphatidylcoline, lecithin in propylene glycol, sunflower mono-diglycerides, ascorbyl palmitate, polysorbate 80 and 1.5%-2.5% ethanol as an anti-adhesive agent in an amount effective to inhibit formation of post-operative adhesions upon local, non-systemic administration of said anti-adhesive agent to said tissue, and a carrier suitable for local prolonged administration of said anti-adhesive agent with minimal systemic circulation where the carrier is selected from a group consisting of microspheres, nanospheres, fibers, polymeric films, gel micelles and drug delivery pumps.
Dependencies are inferred from the claim text.